Speakers

Expand/Collapse

Ahmad Nabhan
Postdoctoral Scholar
Genentech

Day 2

Thursday | April 29, 2021

10:00 am | Comparing & Contrasting Human & Murine Lungs at Single Cell Resolution

Christina Wenglen
Head of Research
AnaMar

Day 1

Wednesday | April 28, 2021

12:00 pm | Evaluating Importance of Serotonin System in Relation to Systemic Sclerosis, Fibrosis & ILDs

Craig Conoscenti
Medical Expert ILD Respiratory Clinical Development & Medical Affairs
Boehringer Ingelheim

Day 1

Wednesday | April 28, 2021

8:30 am | eep Diving in to the Progressive Phenotype of Fibrosing Interstitial Lung Disease

Dinesh Khanna
Professor
University of Michigan

Day 1

Wednesday | April 28, 2021

2:00 pm | Exploring Scleroderma Through the Lens of ILD Clinical Trials: Reviewing Success’, Challenges & Lessons Learned

Gisli Jenkins
Professor
University of Nottingham

Day 1

Wednesday | April 28, 2021

9:30 am | Exploring the Role of TGFbeta in Pulmonary Fibrosis to Evaluate Whether itsIt’s Impact is Healing or Devastating Across Various ILD Phenotypes

Jonathan Chung
Professor of Radiology
The University of Chicago Medicine

Day 2

Thursday | April 29, 2021

2:30 pm | Examining Interstitial lung disease (ILD) assessment on HRCT: Pearls & Pitfalls

Karen Moor
Pulmonologist in Training & Postdoctoral Researcher
Erasmus University

Kevin Brown
Professor &Chair, Department of Medicine
National Jewish Health

Day 1

Wednesday | April 28, 2021

9:00 am | Reviewing Recent Research on Diagnostic Accuracy, Disease Behaviour, & Response Measures

Klaus-Uwe Kirchgässler
Senior Group Global Medical Director
Roche

Day 1

Wednesday | April 28, 2021

3:30 pm | Reviewing Combination Regimes for ILD Treatment: Past, Present, Futur

Mark Hamblin
Assistant Professor, Pulmonary & Critical Care Medicine
University of Kansas Hospital

Marlies Wijsenbeek
Head of the ILD Center
Erasmus University

Day 2

Thursday | April 29, 2021

1:30 pm | Panel Discussion: Benchmarking Experiences of Integrating Home Spirometry in Clinical Trials to Determine Whether Suitable to Use in Your Next Trial

Maximiliano Tamae Kakazu
Assistant Professor of Medicine
Michigan State

Meghan Clements
Principal Research Scientist
AbbVie

Day 2

Thursday | April 29, 2021

9:30 am | nvestigating Next Generation in vivo models: Spotlight on Scleroderma

Mick Foley
La Trobe University & Chief Scientific Officer
AdAlta

Day 1

Wednesday | April 28, 2021

11:30 am | CXCR4/CXCL12: A Common Molecular Axis in Multiple Cell Types with Relevance in ILD

Monica Bengus
Senior Global Medical Director
Roche

Preethi Vijayaraj
Principal Scientist – Drug Concept Discovery, Immunology & Respiratory
Boehringer Ingelheim

Day 2

Thursday | April 29, 2021

9:00 am | Exploring in vitro Systems for Progressive Fibrotic Diseases: Spotlight on Stem Cell Based Models for the Lung

Rohit Batta
Chief Scientific Officer
Vicore Pharma

Toby Maher
Director, Interstitial Lung Disease Program
USC

Day 1

Wednesday | April 28, 2021

1:30 pm | Analyzing Lessons Learned from IPF Clinical Trials to Streamline the Design & Execution of Efficient Clinical Trials for Novel ILD Medicines

Day 2

Thursday | April 29, 2021

1:30 pm | Panel Discussion: Benchmarking Experiences of Integrating Home Spirometry in Clinical Trials to Determine Whether Suitable to Use in Your Next Trial

Joel Matthews
Director Biomarker Assay Research and Assay Development
Ionis

Majd Mouded
Executive Director for BioMedical Research
Novartis

Greg Cosgrove
Vice President Clinical Development
Pliant Therapeutics

Day 1

Wednesday | April 28, 2021

10:00 am | Integrin-Mediated TGF-β Activation: A Crucial Role in Fibrosis

Ling-Pei Ho
Associate Professor Respiratory Immunology
University of Oxford

Day 1

Wednesday | April 28, 2021

11:15 am | Role of monocytes in Pathogenesis of IPF

Emily Fraser
Consultant - Respiratory Medicine
NHS

Iris Alroy
Vice President- R&D
Anima Biotech

Day 1

Wednesday | April 28, 2021

4:30 pm | Targeting Collagen I mRNA Translation in a Tissue Selective Manner With Small Molecules